Franklin Resources Inc. Boosts Holdings in IDEXX Laboratories, Inc. $IDXX

Franklin Resources Inc. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 627,159 shares of the company’s stock after acquiring an additional 54,181 shares during the period. Franklin Resources Inc. owned about 0.79% of IDEXX Laboratories worth $424,291,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories in the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares in the last quarter. Wormser Freres Gestion boosted its position in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares in the last quarter. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IDXX. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $561.17 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The firm has a market capitalization of $44.27 billion, a price-to-earnings ratio of 41.32, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55. The firm has a 50 day moving average of $562.81 and a 200 day moving average of $631.11.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.